Renal response to candoxatrilat in patients with heart failure

Department of Medicine (Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

OBJECTIVES. Our primary objective was to compare the effects of three different doses of candoxatrilat with the effects of placebo on urinary volume in patients with moderately severe heart failure. The effects of candoxatrilat on urinary composition, neuroendocrine indexes and renal hemodynamic function were also studied. BACKGROUND. Candoxatrilat, a neutral endopeptidase inhibitor, reduces degradation of atrial natriuretic peptide and provokes diuresis in patients with mild heart failure, but the renal effects have not been studied in patients with moderately severe heart failure in a placebo-controlled study. METHODS. In a double-blind crossover trial, the effects of intravenous boluses of saline vehicle (placebo) and 50, 100 and 200 mg of candoxatrilat were compared on separate days in 12 patients with heart failure. Urinary output and composition were measured for 8 h. Renal blood flow and glomerular filtration rate were determined by radionuclide techniques. Blood was withdrawn for the measurement of hormones before and 3 h after dosing. RESULTS. All doses of candoxatrilat increased urinary volume (e.g., [mean +/- SEM] 263 +/- 53 to 490 +/- 82 ml for saline solution and the 200-mg dose, respectively, p < 0.01) and sodium content (14 +/- 4 to 37 +/- 11 mmol, p < 0.001) in the 1st 4 h after dosing. Plasma atrial natriuretic peptide increased (140 +/- 26 to 279 +/- 37 pg/ml, p < 0.01), whereas aldosterone decreased (178 +/- 41 to 125 +/- 35 pg/ml, p < 0.01), and renin activity was unchanged (10 +/- 2 to 12 +/- 3 ng/ml per h). CONCLUSIONS. Candoxatrilat given acutely causes diuresis, even in patients with moderately severe heart failure.

This article has been cited by other articles:

				K. Pankow, Y. Wang, F. Gembardt, E. Krause, X. Sun, G. Krause, H.-P. Schultheiss, W.-E. Siems, and T. Walther Successive Action of Meprin A and Neprilysin Catabolizes B-Type Natriuretic Peptide Circ. Res., October 26, 2007; 101(9): 875 - 882. [Abstract] [Full Text] [PDF]

				K. H Chee, K. Amudha, N. A Hussain, H. K Haizal, A.-M. J Choy, and C. C Lang Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 140 - 148. [Abstract] [PDF]

				R. Corti, J. C. Burnett Jr, J. L. Rouleau, F. Ruschitzka, and T. F. Luscher Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? Circulation, October 9, 2001; 104(15): 1856 - 1862. [Abstract] [Full Text] [PDF]

				D. R. McClean, H. Ikram, A. H. Garlick, A. M. Richards, M. G. Nicholls, and I. G. Crozier The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure J. Am. Coll. Cardiol., August 1, 2000; 36(2): 479 - 486. [Abstract] [Full Text] [PDF]

				E. Coodley Newer Drug Therapy for Congestive Heart Failure Arch Intern Med, June 14, 1999; 159(11): 1177 - 1183. [Abstract] [Full Text] [PDF]

				B. Geny, H. Hardy, J. Lonsdorfer, B. Eisenmann, P. Haberey, and F. Piquard Enhanced Natriuretic Response to Neutral Endopeptidase Inhibition in Heart-Transplant Recipients Hypertension, April 1, 1999; 33(4): 969 - 974. [Abstract] [Full Text] [PDF]

				R. E. Chatelain, R. D. Ghai, A. J. Trapani, L. M. Odorico, B. N. Dardik, S. De Lombaert, R. W. Lappe, and C. A. Fink Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 974 - 982. [Abstract] [Full Text]